Projects per year
Abstract
Increasing antibiotic resistance in Gram-negative bacteria, particularly in Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae, presents a global medical challenge. No new antibiotics will be available for these superbugs in the near future due to the dry antibiotic discovery pipeline. Colistin and polymyxin B are increasingly used as the last-line therapeutic options for treatment of infections caused by multidrug-resistant Gram-negative bacteria. This article surveys the significant progress over the last decade in understanding polymyxin chemistry, mechanisms of antibacterial activity and resistance, structure-activity relationships and pharmacokinetics/pharmacodynamics. In the Bad Bugs, No Drugs era, we must pursue structure-activity relationship-based approaches to develop novel polymyxin-like lipopeptides targeting polymyxin-resistant Gram-negative superbugs . Before new antibiotics become available, we must optimize the clinical use of polymyxins through the application of pharmacokinetic/pharmacodynamic principles, thereby minimizing the development of resistance.
Original language | English |
---|---|
Pages (from-to) | 711 - 724 |
Number of pages | 14 |
Journal | Future Microbiology |
Volume | 8 |
Issue number | 6 |
DOIs | |
Publication status | Published - 2013 |
Projects
- 3 Finished
-
Targeting Superbugs: discovery and development of new broad-spectrum lipopeptide
Li, J., Dudley, M. N., Griffith, D., Hecker, S., Lomovskaya, O., Nation, R., Roberts, K., Thompson, P. & Velkov, T.
NIH - National Institutes of Health (United States of America)
1/06/12 → 31/05/17
Project: Research
-
Targeting MD hetero-resistant Gram-negatives: PK/PD for rational combinations.
Nation, R., Li, J., Forrest, A., Paterson, D. L. & Tsuji, B. T.
NIH - National Institutes of Health (United States of America)
15/07/08 → 30/06/12
Project: Research